IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 151-175 out of 1284.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

Public Release: 15-Apr-2016
ELCC 2016 - European Lung Cancer Conference
Plasma genotyping to predict treatment benefit in patients with NSCLC
The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 15-Apr-2016
American Association for Cancer Research Annual Meeting 2016
Low fat diet helps postmenopausal women avoid deadly breast cancers
Women who stayed on a low fat diet for approximately eight years reduced their risk of death from invasive breast cancers and improved their survival rates.
NIH/National Heart, Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services

Contact: Laura Mecoy
Lmecoy@labiomed.org
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)

Public Release: 15-Apr-2016
American Association for Cancer Research Annual Meeting 2016
St. Jude Children's Research Hospital research at AACR Annual Meeting
The American Association for Cancer Research annual meeting features the work of St. Jude researchers.

Contact: Frannie Marmorstein
media@stjude.org
901-595-0221
St. Jude Children's Research Hospital

Public Release: 15-Apr-2016
ELCC 2016 - European Lung Cancer Conference
Patients with EGFR expressing NSCLC benefit most from necitumumab added to chemotherapy
Patients with epidermal growth factor receptor expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference 2016 in Geneva, Switzerland.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 15-Apr-2016
The International Liver CongressTM 2016
Treatment for chronic hepatitis B linked to increased rates of colorectal and cervical cancer
A new study presented today demonstrates a potential link between treatment of long-term oral nucleos(t)ide analogues and an increased risk of colorectal (p=0.029) and cervical (p=0.049) cancer in patients with chronic hepatitis B virus (HBV). The study results were presented at The International Liver CongressTM 2016 in Barcelona, Spain.

Contact: ILC Press office
ilcpressoffice@ruderfinn.co.uk
44-020-743-83054
European Association for the Study of the Liver

Public Release: 15-Apr-2016
American Association for Cancer Research Annual Meeting 2016
Preliminary study: Antibody therapy reduces cancer stem cells in multiple myeloma
An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists.
MedImmune Inc

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 15-Apr-2016
Science Signaling
Researchers identify enzyme link between excessive heart muscle growth, cancer growth
UT Southwestern Medical Center cardiology researchers have identified molecular ties between the growth of cancer cells and heart cells that suggest existing cancer drugs may be able to help those with enlarged heart cells -- a condition that can lead to heart attacks and stroke.
National Institutes of Health, the American Heart Association, the Cancer Prevention and Research Institute of Texas, and the Comisión Nacional de Investigación Cientiffica y Tecnológica

Contact: Cathy Frisinger
cathy.frisinger@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 15-Apr-2016
American Association for Cancer Research Annual Meeting 2016
Experimental drug guadecitabine found safe in patients with colorectal cancer
In a small, phase I clinical trial, Johns Hopkins Kimmel Cancer Center researchers say they show for the first time that the experimental drug guadecitabine (SGI-110) is safe in combination with the chemotherapy drug irinotecan and may overcome resistance to irinotecan in patients with metastatic colorectal cancer.
Astex Pharmaceuticals, Van Andel Research Institute SU2C/AACR Epigenetics Dream Team

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 15-Apr-2016
Journal of Women's Health
Women of color -- what we know and don't know about their unique health challenges
Women of color face both racial and gender disparities in the incidence, onset, and outcomes of diseases as diverse as cancer, cardiovascular disease, HIV infection and age-related disability. The unique health challenges these disparities present are examined in an article published in Journal of Women's Health.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 14-Apr-2016
The International Liver CongressTM 2016
High rate of early cancer recurrence following direct-acting antiviral treatment for hep C virus
A new study fast-tracked for publication today in the Journal of Hepatology has shown that patients with a prior history of hepatocellular carcinoma and who have been treated with direct-acting antivirals for Hepatitis C infection have a higher than expected early recurrence rate of their liver cancer than previously thought -- with the rate in some subgroups exceeding 40 percent.

Contact: ILC Press office
ilcpressoffice@ruderfinn.co.uk
44-020-743-83054
European Association for the Study of the Liver

Public Release: 14-Apr-2016
Oncotarget
Modified flu virus can 'resensitize' resistant pancreatic cancer cells to chemotherapy
A common flu virus could be used to overcome patients' resistance to certain cancer drugs -- and improve how those drugs kill cancer cells, according to new research from Queen Mary University of London (QMUL).
Pancreatic Cancer Research Fund

Contact: Becky Tanner
beckytanner@pcrf.org.uk
44-020-836-01119
Pancreatic Cancer Research Fund

Public Release: 14-Apr-2016
American Association for Cancer Research Annual Meeting 2016
PharmaMar will be present at AACR Congress with novelties in its compounds
PharmaMar will present the latest data obtained on its compounds of marine origin, lurbinectedin, plitidepsin and PM184 at the Annual Congress of the American Association of Cancer Research, that will be held in New Orleans April 16-20. Under the heading 'Delivering Cures Through Cancer Science,' oncologists and investigators from around the world will interchange know-how and reinforce the links between research and the advancements in patient care.

Contact: Paula Fernández
pfalarcon@pharmamar.com
34-638-796-215
Pharmamar

Public Release: 14-Apr-2016
JAMA Oncology
Pitt-led international panel reclassifies thyroid tumor to curb overdiagnosis of cancer
Led by researchers at the University of Pittsburgh School of Medicine, an international panel of pathologists and clinicians have reclassified a type of thyroid cancer to reflect that it is non-invasive and has a low risk of recurrence. The name change is expected to reduce the psychological and medical consequences of a cancer diagnosis, potentially affecting thousands of people worldwide.
University of Pittsburgh Cancer Institute, UPMC, CBLPath, Inc.

Contact: Allison Hydzik
HydzikAM@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences

Public Release: 14-Apr-2016
Cell Reports
Genomic makeup of colorectal cancers predicts immune system ability to fight tumors
Colorectal cancers heavily bedecked with tumor-related proteins called neoantigens are likely to be permeated with disease-fighting white blood cells, researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard report in a new study. Because such an influx of white blood cells often signifies an immune system attack on cancer, the discovery will sharpen research into therapies that make tumors more vulnerable to such an attack.
Harvard Catalyst/The Harvard Clinical and Translational Science Center, National Center for Research Resources and the National Center for Advancing Translational Sciences

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute

Public Release: 14-Apr-2016
Clinical Cancer Research
Lower-carb diet slows growth of aggressive brain tumor in mouse models
University of Florida Health researchers have slowed a notoriously aggressive type of brain tumor in mouse models by using a low-carbohydrate diet.

Contact: Doug Bennett
dougbennett@ufl.edu
352-273-5706
University of Florida

Public Release: 14-Apr-2016
JAMA Oncology
Neratinib plus paclitaxel vs. trastuzumab plus paclitaxel in breast cancer
While neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel as first-line treatment for ERBB2-positive metastatic breast cancer in terms of progression-free survival, the combination was associated with delayed onset and reduced frequency of central nervous system metastases, a finding that requires a larger study to confirm, according to an article published online by JAMA Oncology.

Contact: Ahmad Awada
ahmad.awada@bordet.be
The JAMA Network Journals

Public Release: 14-Apr-2016
Cell
Cancer cells turn healthy cells to the 'dark side'
Cancer cells use a mutant gene to coerce neighboring healthy tissue into helping with the disease's growth and spread, a major new study reports.
Wellcome Trust, Cancer Research UK, Rosetrees Trust

Contact: Henry French
henry.french@icr.ac.uk
020-715-35582
Institute of Cancer Research

Public Release: 14-Apr-2016
American Society of Breast Surgeons annual meeting
Protective mastectomies that preserve nipple safe for women at high breast cancer risk
Protective mastectomies that preserve the nipple and surrounding skin prevent breast cancer as effectively as more invasive surgeries for women with a genetic mutation called BRCA that raises their risk of developing breast cancer, a multi-institution study led by Mayo Clinic found.
National Institutes of Health Specialized Program of Research Excellence in Breast Cancer, Breast Cancer Research Foundation

Contact: Sharon Theimer
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 14-Apr-2016
Biomaterials
Implantable device targets pancreatic cancer
Researchers from MIT and Massachusetts General Hospital have now developed a small, implantable device that delivers chemotherapy drugs directly to pancreatic tumors.
Koch Institute and Dana-Farber/Harvard Cancer Center Bridge Project, Burroughs Wellcome Fund, Koch Institute Cancer Center Support Grant from the National Cancer Institute, Deshpande Center for Innovation at MIT

Contact: Sarah McDonnell
s_mcd@mit.edu
617-253-8923
Massachusetts Institute of Technology

Public Release: 14-Apr-2016
Public Library of Science
Combination therapy may offer better outcomes for patients with retinoblastoma
Researchers at The Saban Research Institute of Children's Hospital Los Angeles (CHLA) have demonstrated that targeting survivin -- a protein that inhibits apoptosis or cell death -- enhances the effectiveness of chemotherapy in cells and mouse models of retinoblastoma (Rb), the most common malignant tumor of the eye in children.
National Institutes of Health, ThinkCure, Las Madrinas Endowment for Experimental Therapeutics in Ophthalmology

Contact: Debra Kain
dkain@chla.usc.edu
323-361-7628
Children's Hospital Los Angeles

Public Release: 14-Apr-2016
Implementation Science
How can lay health advisor programs be designed for maximum impact?
Lay health advisors who share similar backgrounds and values with the medically underserved groups they interact with have been shown to reduce health disparities. Looking to identify elements that can help make these advisors and the programs they support as effective as possible, researchers found that support from the sponsoring organization and clear role expectations are critical for their success. The study is one of the largest to date involving African-American lay health advisors.
NIH/National Cancer Institute

Contact: Stephanie Berger
sb2247@columbia.edu
212-305-4372
Columbia University's Mailman School of Public Health

Public Release: 14-Apr-2016
Onco Targets and Therapy
Potential cholesterol-lowering drug molecule has prostate cancer fighting capabilities
Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting agent. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of prostate cancer, but also can kill cancerous cells.
Department of Defense Prostate Cancer Program

Contact: Jeff Sossamon
sossamonj@missouri.edu
573-882-3346
University of Missouri-Columbia

Public Release: 14-Apr-2016
New England Journal of Medicine
Low-grade brain tumors: Radiation plus chemotherapy is best treatment, trial suggests
New clinical-trial findings show that patients with a low-grade form of brain cancer who are treated with radiation plus a combination of chemotherapy drugs have better survival than patients treated with radiation alone.
NIH/National Cancer Institute

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center

Public Release: 14-Apr-2016
Journal of Nuclear Medicine
SPECT-MRI fusion minimizes surgery for diagnosis of early-stage cervical cancer patients
A recent study reported in the April issue of 'The Journal of Nuclear Medicine' found that cervical cancer patients without enlarged lymph nodes could benefit from SPECT-MRI imaging of their sentinel lymph nodes (SLNs) to assess whether metastases are present.

Contact: Laurie Callahan
lcallahan@snmmi.org
703-652-6773
Society of Nuclear Medicine

Public Release: 14-Apr-2016
Proceedings of the National Academy of Sciences
MDI Biological Laboratory scientist identifies mechanism underlying peripheral neuropathy
Recent research by Sandra Rieger, Ph.D., of the MDI Biological Laboratory identifying the underlying mechanisms of peripheral neuropathy, or nerve damage, has raised the prospect that drug therapies can be developed for the treatment of this condition, which causes pain, numbness and/or tingling in the hands and feet. The research was published March 28 in the Proceedings of the National Academy of Sciences.
NIH/National Institute of General Medical Sciences

Contact: Stefanie Matteson
smatteso@mdibl.org
207-288-9880
Mount Desert Island Biological Laboratory

Showing releases 151-175 out of 1284.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

  Search News Releases

     

 

EurekAlert!